

Abbott Enters Global Partnership To Connect Its World-Leading Continuous Glucose Monitoring System With Medtronic's Insulin Delivery Devices

- Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems
- Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology

ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading¹ FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

The integration of Abbott's CGM sensor with Medtronic's AID algorithms will enable automatic adjustments of insulin to keep glucose in range. The CGM sensor, designed to work exclusively with Medtronic devices, will be developed by Abbott and sold by Medtronic.

AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use intensive insulin as part of their overall therapy. AID systems can benefit people with both Type 1 and Type 2 diabetes who require multiple daily injections of rapid-acting insulin, currently estimated at more than 11 million people globally².

Financial terms of the partnership and timing for commercial availability were not disclosed.

"This partnership pairs two global leaders in glucose sensing technology and insulin delivery," said Jared Watkin, executive vice president of Abbott's diabetes care business. "Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic's insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living."

"Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world," said Que Dallara, executive vice president and president, Medtronic Diabetes. "We're committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care."

This collaboration with Medtronic is the latest in a series of Abbott partnerships aimed at improving and streamlining diabetes care, giving people more choices to confidently administer their insulin. Abbott's Libre single-analyte CGM technology is currently available and integrated with AID offerings from [other insulin delivery companies](#).

About Abbott's Libre Systems

Abbott's Libre portfolio is the world's leading continuous glucose monitoring technology¹, now used by more than 6 million people in more than 60 countries³. Clinical and real-world data from the millions of people that use Libre systems show that the technology helps people improve their glucose control, lower their HbA1c, decrease diabetes-related hospital admissions, and improve their quality of life^{4,5}. The systems have partial or full reimbursement in more than 40 countries.

For important safety information, visit <https://www.freestylelibre.us/safety-information.html>

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on [LinkedIn](#), [Facebook](#), [Instagram](#), [X](#) and [YouTube](#).

1. Data on file, Abbott Diabetes Care. Based on the number of patients assigned to each manufacturer.
2. Fortune Business Insights: [Top Reasons Driving the Demand for Insulin Pumps](#), 2021
3. Data on file, Abbott Diabetes Care.
4. The American Journal of Managed Care, [Flash CGM Associated With Event Reduction in Nonintensive Diabetes Therapy](#) 2021.
5. American Diabetes Association, [Continuous Glucose Monitors](#), accessed March 20, 2024.

SOURCE Abbott

For further information: Abbott Media: Lindsay Delco, Lindsay.Delco@abbott.com, Abbott Financial: Mike Comilla, Michael.Comilla@abbott.com

Additional assets available online:



